See more : MAN SE (MAN.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Vertex Pharmaceuticals Incorporated (VRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex Pharmaceuticals Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The Pacific Securities Co., Ltd (601099.SS) Income Statement Analysis – Financial Results
- Biokarpet S.A. (BIOKA.AT) Income Statement Analysis – Financial Results
- Heart Tronics, Inc. (HRTT) Income Statement Analysis – Financial Results
- ChipMOS TECHNOLOGIES INC. (CPIA.F) Income Statement Analysis – Financial Results
- M3 Metals Corp. (MLGCF) Income Statement Analysis – Financial Results
Vertex Pharmaceuticals Incorporated (VRTX)
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.87B | 8.93B | 7.57B | 6.21B | 4.16B | 3.05B | 2.49B | 1.70B | 1.03B | 580.42M | 1.21B | 1.53B | 1.41B | 143.37M | 102.05M | 175.50M | 199.01M | 216.36M | 160.89M | 102.72M | 69.14M | 161.09M | 167.49M | 78.13M | 61.60M | 44.40M | 43.80M | 13.30M | 22.10M | 19.60M | 27.90M | 3.80M | 3.20M | 2.30M |
| Cost of Revenue | 1.26B | 1.08B | 904.20M | 736.30M | 547.76M | 409.54M | 275.12M | 210.46M | 125.54M | 60.99M | 130.28M | 279.89M | 80.51M | 12.73M | 14.20M | 15.69M | 13.90M | 12.17M | 10.10M | 5.65M | 3.13M | 28.28M | 39.63M | 4.08M | -3.40M | -4.50M | -3.60M | -3.20M | -3.70M | -3.50M | -3.90M | -2.80M | -1.80M | 0.00 |
| Gross Profit | 8.61B | 7.85B | 6.67B | 5.47B | 3.62B | 2.64B | 2.21B | 1.49B | 906.79M | 519.43M | 1.08B | 1.25B | 1.33B | 130.64M | 87.85M | 159.82M | 185.11M | 204.19M | 150.79M | 97.07M | 66.02M | 132.80M | 127.86M | 74.05M | 65.00M | 48.90M | 47.40M | 16.50M | 25.80M | 23.10M | 31.80M | 6.60M | 5.00M | 2.30M |
| Gross Profit Ratio | 87.21% | 87.90% | 88.06% | 88.14% | 86.84% | 86.56% | 88.95% | 87.64% | 87.84% | 89.49% | 89.25% | 81.67% | 94.29% | 91.12% | 86.08% | 91.06% | 93.01% | 94.38% | 93.72% | 94.50% | 95.48% | 82.44% | 76.34% | 94.78% | 105.52% | 110.14% | 108.22% | 124.06% | 116.74% | 117.86% | 113.98% | 173.68% | 156.25% | 100.00% |
| Research & Development | 3.16B | 2.54B | 3.05B | 1.83B | 1.75B | 1.42B | 1.32B | 1.05B | 996.17M | 855.51M | 918.78M | 806.19M | 707.71M | 637.42M | 550.69M | 516.29M | 513.05M | 371.71M | 248.54M | 192.16M | 199.64M | 203.02M | 148.67M | 84.92M | 72.20M | 58.70M | 51.60M | 35.20M | 41.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.43M | 352.58M | 289.21M | 342.74M | 378.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.40M | 24.50M | 16.20M | 19.60M | 58.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.14B | 944.70M | 840.10M | 770.46M | 658.50M | 557.62M | 496.08M | 432.83M | 377.08M | 305.41M | 362.34M | 436.80M | 400.72M | 187.80M | 129.30M | 101.91M | 84.73M | 57.86M | 43.99M | 42.14M | 39.08M | 49.39M | 47.34M | 27.81M | 26.10M | 18.10M | 11.40M | 7.90M | 7.10M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Other Expenses | 475.50M | -164.80M | 4.90M | 296.42M | 192.18M | -790.00K | -81.38M | 4.13M | -6.71M | 30.40M | -72.67M | 44.99M | 124.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| Operating Expenses | 4.78B | 3.49B | 3.89B | 2.60B | 2.41B | 1.97B | 1.82B | 1.48B | 1.37B | 1.16B | 1.28B | 1.24B | 1.11B | 825.22M | 679.98M | 618.20M | 597.78M | 429.57M | 292.53M | 234.30M | 238.72M | 252.41M | 196.01M | 112.73M | 104.60M | 81.30M | 66.60M | 46.30M | 52.30M | 43.80M | 30.60M | 16.60M | 10.60M | 6.40M |
| Cost & Expenses | 6.04B | 4.57B | 4.80B | 3.34B | 2.96B | 2.38B | 2.10B | 1.69B | 1.50B | 1.22B | 1.41B | 1.52B | 1.19B | 837.95M | 694.18M | 633.89M | 611.69M | 441.74M | 302.63M | 239.95M | 241.84M | 280.69M | 235.64M | 116.81M | 101.20M | 76.80M | 63.00M | 43.10M | 48.60M | 40.30M | 26.70M | 13.80M | 8.80M | 6.40M |
| Interest Income | 614.70M | 144.60M | 4.90M | 22.24M | 63.68M | 0.00 | 11.75M | 0.00 | 0.00 | 0.00 | 0.00 | 1.94M | 1.88M | 1.96M | 5.01M | 16.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 44.10M | 54.80M | 61.50M | 58.15M | 58.50M | 34.12M | 57.55M | 81.43M | 84.21M | 72.86M | 22.73M | 14.71M | 36.57M | 19.28M | 13.19M | 13.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 181.30M | 148.30M | 125.60M | 109.52M | 106.94M | 72.42M | 61.40M | 61.40M | 62.34M | 63.26M | 48.37M | 38.19M | 35.04M | 30.46M | 30.11M | 32.20M | 27.46M | 25.87M | 27.29M | 29.64M | 23.44M | 25.43M | 17.96M | 9.10M | 6.30M | 4.50M | 3.60M | 3.20M | 3.70M | 3.50M | 3.90M | 2.80M | 1.80M | 0.00 |
| EBITDA | 4.61B | 4.44B | 2.92B | 3.28B | 1.56B | 706.78M | 103.26M | 75.46M | -411.25M | -598.76M | -554.75M | 42.46M | 133.94M | -704.89M | -598.88M | -426.19M | -385.21M | -199.52M | -114.45M | -107.59M | -264.53M | -123.05M | -97.14M | -24.65M | -44.30M | -43.20M | -15.60M | -36.30M | -22.80M | -17.20M | 5.10M | -7.20M | -3.80M | -4.10M |
| EBITDA Ratio | 46.66% | 48.65% | 36.82% | 51.37% | 35.02% | 21.76% | 12.51% | 0.90% | -45.83% | -105.28% | 41.63% | 0.27% | 15.72% | -461.86% | -531.80% | -260.35% | -189.99% | -93.32% | -56.52% | -101.15% | -96.10% | -58.43% | -14.39% | -18.77% | -52.92% | -62.84% | -35.62% | -127.07% | -128.05% | -106.12% | 13.26% | -242.11% | -143.75% | -178.26% |
| Operating Income | 4.31B | 4.31B | 2.78B | 2.86B | 1.20B | 635.15M | 123.24M | 9.94M | -468.66M | -692.41M | -903.45M | 2.33M | 113.82M | -696.08M | -613.41M | -462.71M | -419.79M | -229.04M | -149.87M | -154.81M | -264.53M | -119.60M | -91.80M | -38.68M | -39.60M | -32.40M | -19.20M | -29.80M | -26.50M | -20.70M | 1.20M | -10.00M | -5.60M | -4.10M |
| Operating Income Ratio | 43.65% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | -45.40% | -119.30% | -74.54% | 0.15% | 8.07% | -485.51% | -601.10% | -263.65% | -210.94% | -105.86% | -93.15% | -150.71% | -382.59% | -74.25% | -54.81% | -49.51% | -64.29% | -72.97% | -43.84% | -224.06% | -119.91% | -105.61% | 4.30% | -263.16% | -175.00% | -178.26% |
| Total Other Income/Expenses | 72.30M | -75.00M | -51.70M | 62.80M | 197.42M | -34.91M | -138.93M | -77.30M | -90.92M | -42.46M | -366.11M | -59.11M | -53.38M | -58.55M | -28.17M | 2.86M | 28.51M | 21.10M | -53.55M | -11.44M | 67.76M | 28.30M | -2.79M | -16.16M | 10.30M | 0.00 | 0.00 | 0.00 | 5.50M | 3.60M | 900.00K | 2.00M | 800.00K | 4.10M |
| Income Before Tax | 4.38B | 4.23B | 2.73B | 3.12B | 1.39B | 600.24M | -15.69M | -67.37M | -559.58M | -734.88M | -976.12M | -12.38M | 60.45M | -754.63M | -642.18M | -464.18M | -426.91M | -206.89M | -173.39M | -158.51M | -347.35M | -119.66M | -117.89M | -53.61M | -40.30M | 0.00 | 0.00 | -39.50M | -21.00M | -17.10M | 2.10M | -8.00M | -4.80M | 0.00 |
| Income Before Tax Ratio | 44.38% | 47.39% | 36.05% | 50.22% | 33.51% | 19.70% | -0.63% | -3.96% | -54.21% | -126.61% | -80.54% | -0.81% | 4.28% | -526.35% | -629.28% | -264.48% | -214.52% | -95.63% | -107.77% | -154.31% | -502.38% | -74.28% | -70.39% | -68.62% | -65.42% | 0.00% | 0.00% | -296.99% | -95.02% | -87.24% | 7.53% | -210.53% | -150.00% | 0.00% |
| Income Tax Expense | 760.20M | 910.40M | 388.30M | 405.15M | 218.11M | -1.49B | -107.32M | 16.67M | 30.38M | 6.96M | -288.57M | 38.75M | 19.27M | 19.28M | 19.34M | -30.73M | -21.39M | -18.50M | 61.68M | 29.01M | 24.06M | -10.98M | -1.92M | 976.00K | 1.40M | 700.00K | 600.00K | 10.20M | -5.00M | -3.10M | 100.00K | -1.50M | -500.00K | 4.30M |
| Net Income | 3.62B | 3.32B | 2.34B | 2.71B | 1.18B | 2.10B | 263.48M | -112.05M | -558.12M | -738.56M | -445.03M | -107.03M | 29.57M | -754.63M | -641.58M | -459.85M | -391.28M | -206.89M | -203.42M | -166.25M | -196.77M | -108.62M | -66.23M | -39.66M | -41.00M | -33.10M | -19.80M | -40.00M | -21.50M | -17.60M | 2.00M | -8.50M | -5.10M | -4.30M |
| Net Income Ratio | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% | 10.59% | -6.58% | -54.06% | -127.25% | -36.72% | -7.01% | 2.10% | -526.35% | -628.70% | -262.02% | -196.61% | -95.63% | -126.43% | -161.85% | -284.59% | -67.43% | -39.54% | -50.76% | -66.56% | -74.55% | -45.21% | -300.75% | -97.29% | -89.80% | 7.17% | -223.68% | -159.38% | -186.96% |
| EPS | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.25 | 1.06 | -0.46 | -2.32 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| EPS Diluted | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.70 | -3.27 | -3.03 | -1.83 | -2.28 | -2.12 | -2.56 | -1.43 | -0.89 | -0.59 | -0.80 | -0.65 | -0.41 | -1.07 | -0.63 | -0.56 | 0.08 | -0.35 | -0.35 | -0.33 |
| Weighted Avg Shares Out | 257.70M | 256.10M | 257.70M | 259.84M | 256.73M | 254.29M | 248.86M | 243.59M | 240.84M | 234.92M | 224.83M | 211.95M | 204.89M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
| Weighted Avg Shares Out (Dil) | 260.50M | 259.10M | 259.90M | 263.40M | 260.67M | 259.19M | 253.23M | 244.69M | 241.31M | 235.31M | 224.91M | 211.95M | 208.81M | 200.40M | 173.26M | 140.56M | 128.99M | 113.22M | 89.24M | 78.57M | 77.00M | 75.75M | 74.46M | 67.68M | 51.04M | 50.60M | 48.53M | 37.38M | 34.13M | 31.43M | 25.00M | 24.29M | 14.62M | 13.03M |
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
Vertex Pharmaceuticals is different from Novo Nordisk in several ways. The two companies could compete against each other in the future.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond
Healthcare and tech remain top areas for long-term investors. Vertex Pharmaceuticals is looking ahead to several near-term launches, while its existing portfolio remains robust.
3 Fantastic Growth Stocks to Buy in August
Eli Lilly is a biopharma giant that could still deliver strong growth. Novo Nordisk's growth story isn't over thanks to Ozempic, Wegovy, and a promising pipeline.
BMY vs. VRTX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.
3 Biotech Stocks to Buy on the Dip: August 2024
With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers...
Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them
Investors should focus on the future, not the past. Four emerging technologies hold tremendous potential.
2 Biotech Stocks To Watch In August 2024
Biotech stocks to keep on your radar this month.
Source: https://incomestatements.info
Category: Stock Reports